Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

NCT02416388 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

3100

Enrollment

OTHER_GOV

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Idarubicin
DRUG: Daunorubicin
DRUG: HD Cytarabine
DRUG: Cyclosporine
DRUG: Methotrexate
DRUG: Mycophenolic acid (MPA)
DRUG: vosaroxin
DRUG: ID cytarabine
DRUG: Dexamethasone
DRUG: Venetoclax

Sponsor

University Hospital, Angers